Julie Beitz

39 papers receiving 1.9k citations

Julie Beitz's Hit Papers

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. 2001 · 660 citations
6600+8+16Years since publication200400600

Peers

Julie Beitz
Comparison fields: 5 of 124
  • Hematology 330
  • Oncology 493
  • Immunology 358
  • Dermatology 148
  • Radiology, Nuclear Medicine and Imaging 301
Replace Susan L. Kelley with:
Susan L. Kelley United States
Gregory D. Ayers United States
John J. Kavanagh United States
Leo B. A. Van De Putte Netherlands
Paul van der Valk Netherlands
Arthur G. Pratt United Kingdom
Yukitaka Ueki Japan
Malcolm Boyce United Kingdom
Chan Zeng United States
Bin Sun China
Julie Beitz relative to Susan L. Kelley United States Susan L. Kelley's profile →
Citations per field
00.5×1.5×1.8×
Susan L. Kelley · 1×
Citations per year

Countries citing papers authored by Julie Beitz

Since Specialization
Citations

This map shows the geographic impact of Julie Beitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Beitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Beitz more than expected).

Fields of papers citing papers by Julie Beitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Beitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Beitz. The network helps show where Julie Beitz may publish in the future.

Co-authors

The 25 scholars most cited alongside Julie Beitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julie Beitz Line = papers co-authored together Julie Beitz links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Hit paper breakdown →
2001660
2 1997174
3 2001159
4 1991130
5
Platelet-derived growth factor indirectly stimulates angiogenesis in vitro.
1993121
6
Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.
199689
7 200285
8 201572
9 199069
10
Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo.
199253
11 200252
12 202034
13 200230
14 200226
15
Predictive value of preclinical toxicology studies for platinum anticancer drugs.
199922
16 199321
17 202021
18 199020
19 200320
20 200419

About Julie Beitz

Julie Beitz is a scholar working on Molecular Biology, Oncology, Immunology, Pharmacology and Epidemiology, having authored 39 papers that have together received 2.0k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (4 papers), Toxin Mechanisms and Immunotoxins (4 papers), Inflammatory mediators and NSAID effects (4 papers), Cancer, Hypoxia, and Metabolism (4 papers), Angiogenesis and VEGF in Cancer (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). The work is most often cited by research in Hematology (330 citations), Oncology (493 citations), Immunology (358 citations), Dermatology (148 citations) and Radiology, Nuclear Medicine and Imaging (301 citations). Julie Beitz has collaborated with scholars based in United States, Thailand and South Korea. Frequent co-authors include A. Raymond Frackelton, Richard Pazdur, Atiqur Rahman, Xi Chen, Gang Chen, Sandip Kumar Roy, Peter Bross, R N Sridhara, Grant Williams and Eamon Duffy. Their work appears in journals such as Cancer, Journal of Investigative Dermatology, Journal of the American Academy of Dermatology, American Journal of Hematology and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact